Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review
Cancers · 20.11.2026 · 18 (22) · 3712
DOI: 10.3390/cancers18223712 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 20.11.2026. Verfasst von Cezara Tudor und 9 weiteren Autor:innen. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bone marrow biopsy (BMB) provides histological information that complements whole-body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). Its clinical value varies across lymphoma subtypes and extends beyond staging.
Methods
This narrative review synthesizes the literature identified through PubMed, Scopus and ScienceDirect searches, supplemented by purposively selected guidelines, foundational studies and citation-linked publications. Recent evidence was prioritized, with older studies retained where needed to explain changes in practice. The synthesis distinguishes diagnostic accuracy, stage migration and consequences for patient management.
Results
Routine staging BMB can generally be omitted in PET-staged Hodgkin lymphoma and in DLBCL without a management-changing question about discordant or alternative marrow pathology. Marrow assessment remains part of guideline-based evaluation in FL, MCL and nodal or splenic MZL, particularly when localized treatment, unexplained cytopenias or diagnostic classification makes the result consequential. Pooled PET/CT sensitivity for FL marrow involvement was 67% (95% confidence interval, 38–87%). In one MCL cohort, the PET/CT-negative predictive value was 27.8% at a composite marrow involvement prevalence of 78.4%, illustrating the importance of disease prevalence and reference standards. FDG avidity of extra-nodal MZL lesions does not establish reliable detection of marrow infiltration. Aspirate-based ancillary tests can clarify clonal or alternative pathology, while ctDNA, radiomics and PET/MRI remain complementary approaches.
Conclusions
Marrow sampling should answer a defined clinical question. Subtype-specific guidance, laboratory abnormalities and the likely consequences of additional tissue information provide the basis for deciding when biopsy is useful.
Zitieren
APA
Tudor, C., Stanciu, A., Adam, T., Stoica, A. G., Gherase-Cristian, M., Popescu, D. M., Savin, D. E., Mircescu, A., Bajenaru, T. S., & Mititelu, R. (2026). Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review. Cancers, 18(22), 3712. https://doi.org/10.3390/cancers18223712
Vancouver
Tudor C, Stanciu A, Adam T, Stoica AG, Gherase-Cristian M, Popescu DM, et al. Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review. Cancers. 2026;18(22):3712. doi:10.3390/cancers18223712
BibTeX
@article{Tudor2026,
author = {Tudor, Cezara and Stanciu, Andreea and Adam, Tatiana and Stoica, Andreea Georgiana and Gherase-Cristian, Miruna and Popescu, Delia Maria and Savin, Dragos Emanuel and Mircescu, Ariadna-Maria and Bajenaru, Teodora Sidonia and Mititelu, Raluca},
title = {Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3712},
doi = {10.3390/cancers18223712}
}
EUVIMED